Author | Year | ClinicalTrials.gov number | Sample size | Histology | Treatment regime | Study phase | Dose (mg/kg) |
---|---|---|---|---|---|---|---|
Doi | 2017 | NCT02564900 | 12 | breast or gastric or gastro-oesophageal carcinomas | trastuzumab deruxtecan | phase 1 | 5·4 or 6·4 |
Park | 2020 | NCT02564900 | 184 | HER2-positive meta- static breast cancer | trastuzumab deruxtecan | phase 2 | 5.4 |
Shitara | 2019 | NCT02564900 | 44 | HER2-positive gastric or gastro-oesophageal junction cancer | trastuzumab deruxtecan | phase 1 | 5·4 or 6·4 |
Tamura | 2019 | NCT02564900 | 115 | HER2-positive breast cancer | trastuzumab deruxtecan | phase 1 | 5·4 or 6·4 |
Modi | 2020 | NCT02564900 | 54 | advanced/metastatic HER2-low–expressing breast cancer | trastuzumab deruxtecan | phase 1 | 5·4 or 6·4 |
Shitara | 2020 | NCT03329690 | 175 (119) a | HER2-positive advanced gastric cancer | trastuzumab deruxtecan as compared with chemotherapy | phase 2 | 6·4 |
Tsurutani | 2020 | NCT02564900 | 59 | HER2-expressing non-breast/non-gastric or HER2-mutant solid tumors | trastuzumab deruxtecan | phase 1 | 6·4 |
Siena | 2021 | NCT03384940 | 78 | HER2-expressing metastatic colorectal cancer | trastuzumab deruxtecan | phase 2 | 4.4 or 5·4 or 6·4 |
Li | 2022 | NCT03505710 | 91 | HER2-mutant non-small-cell lung cancer | trastuzumab deruxtecan | phase 2 | 6·4 |
Modi | 2022 | NCT03734029 | 557 (373) a | HER2-low metastatic breast cancer | trastuzumab deruxtecan as compared with chemotherapy | phase 3 | 5·4 |
Cortés | 2022 | NCT03529110 | 524 (257) a | HER2-positive metastatic breast cancer | trastuzumab deruxtecan as compared with trastuzumab emtansine | phase 3 | 5·4 |